AzTrials
AzTrials

Acute AppendicitisMODRISNCT04207645

Modification and Validation of the RIPASA Score for Diagnosis of Acute Appendicitis

An observational study of Acute Appendicitis, run by Soba University Hospital at 37 sites in 6 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Purpose: The diagnostic approach of patients with acute appendicitis (AA) remains debated. A number of clinical prediction rules (CPRs) exist for diagnosis of AA with variable sensitivity, specificity, and diagnostic accuracy, in different ethnic populations. Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
Acute Appendicitis
What is being tested?
Modified RIPASA score
How many people
240 participants
Where
37 sitesin 6 countries
Study dates
1 Nov 2019to 30 Jun 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All consecutive patients age ≥ 16 years with acute right iliac fossa (RIF) pain or suspected acute appendicitis who are attending the acute services of the participating surgical departments during the study period and who has none of the exclusion criteria will be included.

Who may be able to join

  • all consecutive patients age ≥ 16 years, who are referred to the on-call surgeon's team with acute right iliac fossa (RIF) pain or suspected acute appendicitis, will be included.

Who cannot join

  • history of previous appendicectomy
  • previous abdominal surgery in the last 90 days
  • history of chronic abdominal pathology (e.g. ovarian cyst, colitis .. etc)
  • history of inguinal hernia
  • pregnancy

Trial locations and contacts

37 sites in 6 countries.

37 sites in 6 countries

Mexico10 sites
  • Hospital General de Amecameca Valentin Gomez Farías

    Amecameca de Juárez

  • Civil Hospital Culiacan

    Culiacán

  • General Hospital of Culiacan

    Culiacán

  • Hospital General de Culiacan "Dr. Bernardo J. Gastelum"

    Culiacán

  • ISSSTE Regional Hospital of Culiacan

    Culiacán

  • Hospital Civil de Guadalajara

    Guadalajara

  • Hospital General del estado de Sonora "Dr. Ernesto Ramos Bours"

    Hermosillo

  • Hospital General de Mexico

    Mexico City

  • Hospital General Dr. Manuel Gea Gonzalez

    Mexico City

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

    Mexico City

Other trials in Mexico

Spain8 sites
  • Santos Reyes Hospital

    Aranda de Duero

  • Hospital General Mateu Orfila

    Menorca

  • Digestive Surgery Department, Hospital Universitario Son Espases

    Palma de Mallorca

  • Hospital Universitario Nuestra Señora de Valme

    Seville

  • Hospital universitario Virgen Macarena

    Seville

  • Department of General Surgery, Medina del Campo Hospital

    Valladolid

  • Río Hortega University Hospital

    Valladolid

  • University Clinical Hospital of Valladolid

    Valladolid

Other trials in Spain

Nigeria7 sites
  • Ekiti State University Teaching Hospital

    Ado-Ekiti

  • Federal Medical Centre

    Birnin Kebbi

  • Aminu Kano Teaching Hospital

    Kano

  • Department of Surgery, Lagos University Teaching Hospital

    Lagos

  • Fedral Medical Centre

    Owerri

  • Department of Surgery, Port Harcourt University Hospital

    Port Harcourt

  • Rivers State University Teaching Hospital

    Port Harcourt

Other trials in Nigeria

India5 sites
  • Azeezia institute of medical sciences and research

    Kollam

  • Baby memorial hospital

    Kozhikode

  • Government Medical college and hospital

    Kozhikode

  • Jubilee Mission Medical College and Research Institute

    Thrissur

  • Believers church Medical college hospital

    Tiruvalla

Other trials in India

Pakistan5 sites
  • Department of Surgery, Pakistan Air Force Hospital

    Lahore

  • Fatima Memorial Hospital

    Lahore

  • Combined Military Hospital

    Multan Khurd

  • Combined Military Hospital

    Rawalpindi

  • Fauji Foundation Hospital

    Rawalpindi

Other trials in Pakistan

Sudan2 sites
  • Al Mawada Hospital

    Khartoum

  • Ibrahim Malik Teaching Hospital

    Khartoum

Other trials in Sudan

About this study

Official title: Modification and Validation of the RIPASA Score for Diagnosis of Acute Appendicitis Across Different Ethnic Populations (MODRIS): An International Multicentre Study

Purpose: The diagnostic approach of patients with acute appendicitis (AA) remains debated. A number of clinical prediction rules (CPRs) exist for diagnosis of AA with variable sensitivity, specificity, and diagnostic accuracy, in different ethnic populations. Among these, the Raja Isteri Pengiran Anak Saleha Appendicitis (RIPASA) score was shown to have a high sensitivity though with a poor specificity. The aim of this study is to modify and validate the RIPASA score in 4 distinct ethnic groups, and to compare the performance of the new score to the original RIPASA and Alvarado scores.

Methods: This multicenter, international prospective observational study will be conducted in 6 countries, and will include all eligible patients referred to surgical specialists with acute right iliac fossa pain or suspected AA in the participating centres. Patients will be categorized into 4 ethnic groups based on the country of origin. The modified RIPASA score will be developed in one ethnic group, and along with the original RIPASA and Alvarado scores, will be externally validated in the other 3 ethnic groups. Management of patients will be prospectively evaluated in a standardized manner. The focus of the analysis will be on the performance of the 3 CPRs in different ethnic and gender groups using receiver operating characteristic curve analyses.

Discussion: We expect this study to develop a CPR that can assist surgeons and surgical residents to early identify patients with AA in the busy clinical and low-resource settings, and to optimize the diagnostic value of the RIPASA and Alvarado scores in different ethnic and gender groups.

Read the detailed description

Introduction Acute appendicitis (AA) is the most common abdominal emergency requiring emergency surgery, and its preoperative clinical diagnosis remains a vexing challenge. Several clinical prediction rules have been developed to facilitate diagnosis of AA, and to predict severity of the disease, nonetheless there has been a controversy regarding the benefit of these CPRs in reducing negative appendicectomy rates and costs and improving surgical outcomes. Among these, the Alvarado score is the most commonly validated CPR, followed by Kalan's modified Alvarado score. The latter CPR is more user friendly and almost equally sensitive though less accurate than the original Alvarado score. Both scores are however more useful when used as "rule out" rather than "rule in" diagnostic tools, particularly in female patients of child-bearing age. Moreover, while numerous reports have demonstrated that these scores are reliable Clinical predictors for AA in western countries, parallel studies failed to replicate these results in different ethnic populations. This was partially ascribed to variations in the characteristics of the evaluated patients, and variable interpretation of variables by different clinicians in different settings.

The Raja Isteri Pengiran Anak Saleha Appendicitis (RIPASA) score, which is based on 15 clinical and laboratory parameters, has been recently validated by Erdem and colleagues, and compared to other three CPRs including the Alvarado score. The RIPASA score presented the highest sensitivity (100%, cut-off value of 7.5), whereas it had a poor specificity (28%). The diagnostic accuracies of the scoring systems however were almost comparable. In a recent meta-analysis conducted by Frountzas et al, culling data from 12 studies, the RIPASA score showed superior sensitivity (94% vs 69%) and area under curve (AUC) value (0.94 vs 0.79), and a lower specificity (55% vs 77%) compared to the Alvarado score. More importantly, ten out of the 12 studies in this analysis were carried out in Asian, Middle Eastern, and Latin American patients and evidenced that the RIPASA score consistently outperformed the Alvarado score in terms of diagnostic accuracy and sensitivity. On the other hand, none of the studies included African patients, and only two studies were conducted in western populations, showing conflicting results.

A recent study has shown that the most reliable laboratory parameters in the diagnosis of AA are primarily "neutrophilia" and secondarily "leukocytosis". Nonetheless, different cut-off values for these predictors have been suggested in the literature. In a well-designed prospective blinded trial, Dueholm et al. demonstrated that the interquartile range (25%-75%) of the total white blood cell (WBC) count (x 109/ l) for "No appendicitis" and "Appendicitis" was 7.1-11 vs 11-16.3, respectively. The corresponding figures for neutrophils were 60-80% and 75-88%, respectively. The authors assessed the diagnostic value of tests combinations, and indicated that a diagnostic model using WBC > 11 (x 109/ l) as a cut-off value has the highest efficiency, with a negative predictive value of 98%. In contrast, Iyrik et al. showed that WBC count of 12 (x 109/ l) and neutrophils of 73% were the optimal cut-off values to discriminate between "Appendicitis" and "No appendicitis". Of note, the cut-off value for leukocytosis in the RIPASA score is not clearly defined, and the parameter "neutrophilia" is not included. Therefore and in light of the current evidence, we would like to introduce some modifications to the RIPASA score in order to improve the specificity and to make it simpler, reproducible, and applicable to busy clinical settings.

Methods Hypothesis and objectives The hypothesis is that a better understanding of the performance of CPRs in relation to ethnic differences may improve their diagnostic value and may have a role in avoiding unnecessary operations, reducing the negative appendicectomy rate and improving patient outcomes.

The primary objective of this study is to develop a modification of the RIPASA score in a Latin American population, and to externally validate the modified RIPASA (MODRIS) score in 3 other ethnic populations (European, African, and South Asian). For comparison, the performance of the original RIPASA and Alvarado scores will also be analyzed.

Secondary objectives are:

  • To determine the specificity (the ability to diagnose non-appendicitis) and the sensitivity (the ability to diagnose acute appendicitis) of each CPR, based on the optimal cut-off on the receiver operating characteristic (ROC) curve.
  • To determine the failure rate for each CPR, defined as the proportion of patients stratified to the "low-risk" group who do have appendicitis (reciprocal of the negative predictive value).
  • To assess the postoperative outcomes, including negative appendicectomy rate, in patients who are classified as "low-risk" by each CPR. Accordingly, an algorithm will be proposed for management of low-risk patients in each ethnic group.

Study setting and participants For this prospective multicentre cohort study, recruitment of the study subjects will take place in the participating centres in 6 countries during the study period November 1st 2019 to May 31th 2020. Patients will be stratified according to the country of origin into four ethnic groups: "African" originating from Nigeria and Sudan, "Latin American" originating from Mexico, "South Asian" originating from India and Pakistan, and "European" originating from Spain.

Ethics and informed consent This study is conducted in accordance with the declaration of Helsinki. Participation in the study does not oppose a risk greater or different from the general surgical treatment of patients with RIF pain. To ensure data anonymity, no patient identifiable information will be collected by the main data manager. The study protocol was approved by the medical ethics committee of the trial coordinating centre (Soba University Hospital, Sudan, ID: 201903311). In other countries, local lead investigators were responsible for arranging research ethics committee or institutional approval locally, as appropriate. The study has been registered in the ClinicalTrials.gov database (ID: NCT04207645).

Patient management and follow-up During the study period, the decision to operate on patients will depend on the surgeon's judgement, imaging findings, or both, and not any appendicitis scoring results. With the exception of the main investigators, all researchers who are involved in the data collection will be blinded to the three CPRs under evaluation. This is to ensure that predictors are assessed blinded to outcome. The clinical data of patients will prospectively be collected during the initial evaluation using standardized case report forms. These include demographics, clinical findings, laboratory investigations, imaging studies, operative details, and postoperative course. All patients, including those who are managed conservatively, will be followed up for 1 month to assess for postoperative adverse events or whether they required a subsequent operation.

The patients will be dichotomized into two groups: "No appendicitis" group comprises patients who are managed conservatively, underwent negative appendicectomy, or have diagnoses other than AA, and "Appendicitis" group comprises patients who have histologically confirmed AA.

Brief centre survey:

At each participating centre, a consultant surgeon has completed a brief survey regarding the service characteristics and the clinical pathway of management of patients with RIF pain in their hospital.

Definitions:

  • Acute appendicitis is strictly defined as presence of acute inflammation, i.e polymorphonuclear infiltration in the muscularis propria of the appendix.
  • Complicated appendicitis: defined as histologically or intraoperatively diagnosed gangrenous appendicitis, perforated appendicitis, and appendicitis with an abscess or periappendicular mass.
  • Negative urinalysis: absence of Red cells, WBCs, or bacteria.
  • 30-day adverse events: these include wound infection, intraabdominal/pelvic abscess, unscheduled postoperative imaging, reintervention, readmission, or unexpected adverse postoperative event within 30 days of surgery on index admission.

Predictors change:

  • Omission of the "Rovsing's sign" and the "foreign national identity card". The former clinical sign is subjective and time consuming, and latter parameter has been included by the authors as there was a high percentage of foreign nationals who do not have free access to medical services in emergency settings. These circumstances are not applicable to many other countries. Furthermore, omitting the "foreign national identity card" parameter in two previous studies did not adversely affect the results.
  • Including "neutrophil percentage" as a predictor in the new CPR, which has a good predictive value (0.91), with a fair sensitivity (0.71). We hypothesize that this addition will bolster the diagnostic accuracy.
  • A total of 14 candidate predictors will be used to construct the MODRIS score.

Sample size calculation The study population comprises a development and internal validation cohort (Latin American group), and 3 external validation cohorts (European, South Asian, and African groups). In each of the 4 groups, the sample size calculation will be based on a planned interim analysis that will be carried out at the start of the trial, and will involve the first 200 patients. The patients of this internal pilot study will be included in the validation cohorts. In the Latin American group, the number of final candidate predictors will be determined based on calculation of the number of events, and this is to verify an events-per-variable rate greater than 20. In each of the external validation cohort, an algorithm based on a binary logistic regression model, recently described by Palazon-Bru et al., will be used to estimate the required sample size for external validation of the MODRIS score. This method uses smooth curves rather than risk categorization, thereby providing greater validity to the results. Based on the results of the survey, it is anticipated that centres in each geographical region (5-11 centres per region) will capture a total of 60-200 patients with RIF pain per month. Recruitment will continue in each region until the estimated sample size is reached.

Statistical analysis Statistical analysis will be performed using SPSS version 22.0 (IBM corp., Armonk, NY, USA) and R 3.5.1 (Foundation for Statistical Computing, Vienna, Austria). Normal distribution of data will be assessed using visual inspection of histograms. Normally distributed data will be presented as mean with standard deviation (SD) and non-normally distributed data will be presented as median with interquartile range (IQR). Categorical variables will be presented as counts and proportions. Comparisons between groups will be performed using both parametric and non-parametric tests as appropriate. A two-sided significance level of P < 0.05 will be considered statistically significant. Missing data will be explored and if the percentage exceeds 10 % a multivariate imputation with chained equations will be performed.

Development and internal validation of the MODRIS score: four continuous predictors (age, temperature, WBC count, and neutrophil percentage) will be transformed into basic cubic splines to determine the functional form of these predictors regarding the outcome risk. All candidate predictors, including all splines transformations of the continuous predictors, will be included in a logistic regression model and then a backward elimination method based on the likelihood ratio test (P < 0.25) will be applied to select the final predictors. In addition, gender will be included as a variable and interaction term for all symptoms and signs. The model will be adapted to a scoring system using the Framingham Heart Study methodology. The MODRIS score will be internally validated through a bootstrap technique with 1000 random samples. Discrimination will be assessed by calculation of area under the receiver-operator characteristic curve, whilst calibration will be obtained through the construction of smooth curves.

External validation: the MODRIS score will be externally validated in 3 ethnic groups. Simultaneously, discrimination of the RIPASA and Alvarado scores will be determined, and the DeLong test will be used to compare the difference between the AUCs of the 3 CPRs. The ROC analyses will be used to calculate the optimal cut-off value for the 3 CPRs in each ethnic group. The specificity, sensitivity, and negative predictive value will also be calculated. Based on the optimal cut-off value, patients will be stratified into "low risk" and "high risk" groups. An ideal CPR would achieve the highest specificity while maintaining a negative predictive value of ≥ 95% in the low-risk group. The postoperative outcomes of "low risk" groups will be compared between CPRs. In addition, gender-specific analysis will be carried out to assess the performance of the CPRs in each gender group.

Discussion The current study aims to externally validate the MODRIS score, and to compare it to the original RIPASA and the widely used Alvarado score in 3 distinct ethnic groups, using a large, prospective international cohort. Although several previous studies have validated the latter two CPRs, most were either underpowered or had a retrospective design.

In a recent multicentre study in Europe validating 12 CPRs for AA, the Adult Appendicitis and Appendicitis Inflammatory Response (AIR) scores were found to be the best performers. Nevertheless, both scores require C-reactive protein (CRP) measurement for their calculation. We did not include CRP level in the MODRIS score which makes it particularly useful in low-resource settings with limited access to diagnostic investigations. Although it correlates well with the severity of the disease and postoperative complications, a single CRP reading has only a modest positive predictive ability for AA, and its incorporation as an adjunctive test in the modified Alvarado score did not improve the diagnostic accuracy of the scoring system. Moreover, the MODRIS score maintains the advantages of the RIPASA score such as it requires calculation only at a single point in time, does not require special clinical experience, and includes the gender factor, thereby ensuring a lower false-positive rate of AA in female patients compared to Alvarado score.

Implications for clinical practice Previous reports have indicated that AA in developing countries with limited resources has a different disease profile compared to that described in the developed world. It is associated with prolonged delays to definitive surgical care, significant morbidity, and poor outcome, which are partially ascribed to a much wider range of differential diagnoses of RIF pain than in the developed world, resulting in failure to early diagnose the condition. In another aspect, Scarborough et al. compared the postoperative outcomes of African and White American patients undergoing appendicectomy for AA. The analysis showed that the black race was independently associated with increased incidence of serious and overall postoperative complications. The authors suggested that blacks may suffer a delay in either diagnosis or management of appendicitis relative to whites. Clinical prediction rules have been advocated by several authors as one of the suggested strategies to improve outcomes of AA by facilitating clinical decision-making among junior doctors. Optimizing the diagnostic value of CPRs in different ethnic groups may help to improve the quality and safety of care and effectiveness of the management of patients suspected for AA, particularly in African patients and in resource-constraint environments.

Limitations By the very nature of the multicentre design of the study and the variable clinical and laboratory assessment of patients in different centres, inter-observer variability is expected to present in the dataset and this may impact the internal validity of the study. However, efforts were made to minimise this inherent bias by recruiting centres from a limited number of countries, which are likely to follow a similar clinical pathway of management of AA. Data collection will be carried out using standardized forms designed to be completed at the patient's bedside, to reduce measurement and recall bias. Another limitation of the study is that the follow-up is limited to 30 days after the index hospital admission. It is possible that a proportion of patients who are managed conservatively may subsequently undergo appendicectomy either at other hospitals or beyond the 30-day follow-up. Furthermore, although we are trying to achieve high levels of case ascertainment, it is possible that a small number of eligible patients may be missed during the study period.

Being tested
Modified RIPASA score
Keywords
Appendicitis, modified RIPASA score, Clinical prediction rule, Validation, Ethnic group
Medical subject headings
Appendicitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Modified RIPASA scoreDiagnostic test

    Also called RIPASA score and Alvarado score

    Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis

Study groups in NCT04207645
Study groupRoleWhat they receive
Africanpatients originating from Nigeria and Sudan (11 centres)
Receives: Diagnostic Test: Modified RIPASA score
Latin Americanpatients originating from Mexico (5 centres)
Receives: Diagnostic Test: Modified RIPASA score
South Asianpatients originating from India and Pakistan (10 centres)
Receives: Diagnostic Test: Modified RIPASA score
Europeanpatients originating from Spain (11 centres).
Receives: Diagnostic Test: Modified RIPASA score

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Performance of each clinical prediction rule (modified RIPASA, RIPASA, and Alvarado score)

    Performance is discrimination between appendicitis and no appendicitis

    Measured: 1 month

Secondary outcomes (4)
  1. sensitivity of each clinical prediction rule

    the ability to diagnose acute appendicitis

    Measured: 1 month

  2. specificity of each clinical prediction rule

    the ability to diagnose non-appendicitis

    Measured: 1 month

  3. Failure rate for each clinical prediction rule

    defined as the proportion of patients stratified to the "low-risk" group who do have appendicitis (reciprocal of the negative predictive value)

    Measured: 1 month

  4. Postoperative outcomes, including negative appendicectomy rate, in patients who are classified as "low-risk" by each clinical prediction rule

    Postoperative outcomes include complications, reintervention, readmission and negative appendicectomy rates

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2019
  2. Study start1 Nov 2019
  3. Primary completion30 Jun 2020
  4. Study completion30 Jun 2020

Why it stopped: Poor recruitment and some centers were not able to secure ethics approval/exemption. The study will be repeated all over again with additional centers, secured approvals/exemptions, and when things are ready

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
240 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04207645
Sponsor's protocol ID
201903311
Acronym
MODRIS
Status last verified
Mar 2021
First submitted
19 Dec 2019
Last updated
23 Mar 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Kularatna M, Lauti M, Haran C, MacFater W, Sheikh L, Huang Y, McCall J, MacCormick AD. Clinical Prediction Rules for Appendicitis in Adults: Which Is Best? World J Surg. 2017 Jul;41(7):1769-1781. doi: 10.1007/s00268-017-3926-6.

    PubMed 28258458
  • Kalan M, Talbot D, Cunliffe WJ, Rich AJ. Evaluation of the modified Alvarado score in the diagnosis of acute appendicitis: a prospective study. Ann R Coll Surg Engl. 1994 Nov;76(6):418-9.

    PubMed 7702329
  • Ohle R, O'Reilly F, O'Brien KK, Fahey T, Dimitrov BD. The Alvarado score for predicting acute appendicitis: a systematic review. BMC Med. 2011 Dec 28;9:139. doi: 10.1186/1741-7015-9-139.

    PubMed 22204638
  • Al-Hashemy AM, Seleem MI. Appraisal of the modified Alvarado Score for acute appendicits in adults. Saudi Med J. 2004 Sep;25(9):1229-31.

    PubMed 15448772
  • Khan I, ur Rehman A. Application of alvarado scoring system in diagnosis of acute appendicitis. J Ayub Med Coll Abbottabad. 2005 Jul-Sep;17(3):41-4.

    PubMed 16320795
  • Ozkan S, Duman A, Durukan P, Yildirim A, Ozbakan O. The accuracy rate of Alvarado score, ultrasonography, and computerized tomography scan in the diagnosis of acute appendicitis in our center. Niger J Clin Pract. 2014 Jul-Aug;17(4):413-8. doi: 10.4103/1119-3077.134001.

    PubMed 24909462
  • Bhattacharjee PK, Chowdhury T, Roy D. Prospective evaluation of modified Alvarado score for diagnosis of acute appendicitis. J Indian Med Assoc. 2002 May;100(5):310-1, 314.

    PubMed 12418631
  • Tade AO. Evaluation of Alvarado score as an admission criterion in patients with suspected diagnosis of acute appendicitis. West Afr J Med. 2007 Jul-Sep;26(3):210-2. doi: 10.4314/wajm.v26i3.28311.

    PubMed 18399336
  • Erdem H, Cetinkunar S, Das K, Reyhan E, Deger C, Aziret M, Bozkurt H, Uzun S, Sozen S, Irkorucu O. Alvarado, Eskelinen, Ohhmann and Raja Isteri Pengiran Anak Saleha Appendicitis scores for diagnosis of acute appendicitis. World J Gastroenterol. 2013 Dec 21;19(47):9057-62. doi: 10.3748/wjg.v19.i47.9057.

    PubMed 24379631
  • Frountzas M, Stergios K, Kopsini D, Schizas D, Kontzoglou K, Toutouzas K. Alvarado or RIPASA score for diagnosis of acute appendicitis? A meta-analysis of randomized trials. Int J Surg. 2018 Aug;56:307-314. doi: 10.1016/j.ijsu.2018.07.003. Epub 2018 Jul 12.

    PubMed 30017607
  • Tanrikulu CS, Karamercan MA, Tanrikulu Y, Ozturk M, Yuzbasioglu Y, Coskun F. The predictive value of Alvarado score, inflammatory parameters and ultrasound imaging in the diagnosis of acute appendicitis. Ulus Cerrahi Derg. 2015 Jun 1;32(2):115-21. doi: 10.5152/UCD.2015.3103. eCollection 2016.

    PubMed 27436936
  • Dueholm S, Bagi P, Bud M. Laboratory aid in the diagnosis of acute appendicitis. A blinded, prospective trial concerning diagnostic value of leukocyte count, neutrophil differential count, and C-reactive protein. Dis Colon Rectum. 1989 Oct;32(10):855-9. doi: 10.1007/BF02554555.

    PubMed 2676422
  • Chong CF, Adi MI, Thien A, Suyoi A, Mackie AJ, Tin AS, Tripathi S, Jaman NH, Tan KK, Kok KY, Mathew VV, Paw O, Chua HB, Yapp SK. Development of the RIPASA score: a new appendicitis scoring system for the diagnosis of acute appendicitis. Singapore Med J. 2010 Mar;51(3):220-5.

    PubMed 20428744
  • Khalil OA (2013) Using of the modified RIPAS score in diagnosis of acute appendicitis to decrease use of abdominal computed tomography. Egyptian J Surg 32:86-90.

  • Alvarado A. A practical score for the early diagnosis of acute appendicitis. Ann Emerg Med. 1986 May;15(5):557-64. doi: 10.1016/s0196-0644(86)80993-3.

    PubMed 3963537

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Appendicitis, run by Soba University Hospital at 37 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 23 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 37 sites in Mexico, Spain, Nigeria, India, Pakistan and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Poor recruitment and some centers were not able to secure ethics approval/exemption. The study will be repeated all over again with additional centers, secured approvals/exemptions, and when things are ready). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Performance of each clinical prediction rule (modified RIPASA, RIPASA, and Alvarado score) (time frame: 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04207645, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in